Industry Insights by Jeremy Levin, Chair and CEO of Ovid Therapeutics and Board Chair of BIO (AdvanSE Life Sciences Conference 2020)
On November 11, 2020, I had the pleasure of participating in a virtual fireside chat with Dr. Jeremy Levin at the first AdvanSE Life Sciences Conference held by the Southeast Life Sciences Association. Dr. Levin has a long and rich resume in the biopharma industry. For example, he played a pivotal role in the Bristol-Myers Squibb acquisition of Medarex and BMS’s entry into the immunooncology field. Dr. Levin currently is leading Ovid Therapeutics, a biopharma company, through its phase three trials for treatment of Angelman syndrome, a rare neurological disease.
During our discussion, Dr. Levin provided candid insights as to the past, present, and future of the life sciences industry and BIO, where he current serves as the Board Chair. Dr. Levin reminded us that the innovations in the life sciences industry are strategic assets that must be valued. Biotechnology is relatively new but he has watched it grow into an industry that, in a moment of crisis like the COVID-19 pandemic, was able to rapidly develop and deploy vaccines, anti-viral treatments, and testing.
Dr. Levin noted the migration of biotech innovations from small companies that are more innovative to large companies that are more powerful. He predicts that, just as immunooncology exploded in the past, neuroscience will explode next and that, with each new biopharmaceutical agent for treatment of neurological diseases, we will learn more about the central nervous system. He discussed lessons the life sciences industry will take away from the COVID-19 pandemic – need for zero political influence at the FDA, CDC, and NIH; criticality of epidemiological research; means for rapid manufacture and distribution of biopharmaceuticals; and government/industry communication in a way that promotes trust.
Dr. Levin also addressed healthcare disparities as well as the need to embrace biosimilars with effective regulations and guidelines. Dr. Levin warned us that we sometimes must be prepared “to stick our necks out” for innovation to thrive. Each development creates another shoot that has the potential to flourish.
This summary cannot fully capture the inspiration and excitement Dr. Levin’s remarks conveyed. The recorded program is available at https://youtu.be/0U48BiSfBnE.
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.